Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

166

projects in our pipeline

12

new molecular entities in our late-stage pipeline

2

new molecular entity new to phase 3

Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).

Filter By:

Oncology (as of 30 April 2021)

Phase I

Phase I

  • AZD0466 haematological and solid tumours
  • AZD1390 glioblastoma
  • AZD4573 haematalogical malignancies
  • AZD5305 solid tumours
  • AZD5991 haematalogical malignancies
  • AZD7648 haematological and solid tumours
  • AZD8701 solid tumours
  • Calquence (platform) PRISM relapsed/refractory aggressive non-hodgkin’s lymphoma
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + CTx 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • IPH5201 solid tumours
  • MEDI1191 solid tumours
  • MEDI5395 solid tumours
  • MEDI5752 + axitinib advanced renal cell carcinoma
  • MEDI9253 solid tumours
  • Tagrisso + (Koselugo or savolitinib) TATTON advanced EGFRm non-small cell lung cancer

Phase II

Phase II

  • (oleclumab+CTx) or (Imfinzi+oleclumab+CTx) metastatic pancreatic cancer
  • adavosertib ovarian cancer, solid tumours, uterine serous cancer
  • AZD2811 nanoparticle solid tumours, haematological malignancies
  • camizestrant (AZD9833) oestrogen receptor +ve breast cancer
  • capivasertib prostate cancer
  • ceralasertib solid tumours
  • Imfinzi (platform) BALTIC ES-SCLC refractory/resistant
  • Imfinzi (platform) COAST non small cell lung cancer
  • Imfinzi (platform) HUDSON post IO non-small cell lung cancer
  • Imfinzi (platform) NeoCOAST non-small cell lung cancer
  • Imfinzi + FOLFOX + bevacizumab COLUMBIA 1 1st-line metastatic microsatellite-stable colorectal cancer
  • Imfinzi + imaradenant (AZD4635) + cabazitaxel prostate cancer
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + Lynparza ORION 1st-line metastatic non-small cell lung cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer
  • MEDI5752 solid tumours
  • Post-1L Tagrisso ORCHARD (platform) EGFRm non-small cell lung cancer
  • Tagrisso + savolitinib SAVANNAH advanced EGFRm non-small cell lung cancer

Phase III

Phase III

  • camizestrant (AZD9833) + palbociclib SERENA-4 1st-line HR+ HER2- breast cancer
  • capivasertib + CTx CAPItello-290 1st-line metastatic triple negative breast cancer
  • capivasertib + fulvestrant CAPItello-291 locally advanced (inoperable) or metastatic breast cancer
  • capivasertib# + abiraterone CAPItello-281 PTEN deficient metastatic hormone sensitive prostate cancer
  • datopotamab deruxtecan TROPION-Lung01 2L+ NSCLC without actionable genomic mutations
  • Enhertu DESTINY-Breast01 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with T-DM1
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi +/- tremelimumab + CRT ADRIATIC 1st-line limited-stage small-cell lung cancer
  • Imfinzi +/- tremelimumab + CTx POSEIDON 1st-line non-small cell lung cancer
  • Koselugo/selumetinib SPRINT paediatric neurofibromatosis type-1
  • Lumoxiti 3rd-line hairy cell leukaemia
  • Lynparza + Imfinzi DUO-E 1st-line endometrial cancer
  • Lynparza + Imfinzi + bevacizumab DUO-O 1st-line ovarian cancer
  • monalizumab + cetuximab INTERLINK-1 2L+ relapsed metastatic head and neck squamous cell cancer

LCM Projects

LCM Projects

  • Calquence ECHO 1st-line mantle cell lymphoma
  • Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
  • Calquence ELEVATE-RR relapsed/refractory chronic lymphocytic leukaemia, high risk
  • Calquence ELEVATE-TN 1st-line chronic lymphocytic leukaemia
  • Calquence + R-CHOP ESCALADE 1st-line Diffuse Large B Cell Lymphoma
  • Calquence + venetoclax + obinutuzumab AMPLIFY 1st-line chronic lymphocytic leukaemia
  • Enhertu DESTINY-Breast03 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • Enhertu DESTINY-Breast05 HER2-positive post-neoadjuvant high-risk breast cancer
  • Enhertu DESTINY-Breast06 post-ET HER2low/HR+ breast cancer 2L
  • Enhertu DESTINY-CRC01 HER2-expressing advanced colorectal cancer
  • Enhertu DESTINY-Gastric01 HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens
  • Enhertu DESTINY-Gastric02 HER2-positive gastric cancer that cannot be surgically removed or has spread
  • Enhertu DESTINY-Lung01 HER2-over-expressing or -mutated, unresectable and/or metastatic non-small cell lung cancer
  • Enhertu DESTINY-PanTumour01 HER2-expressing solid tumors
  • Enhertu DESTINY-PanTumour02 HER2-expressing solid tumors
  • Enhertu DESTINY-Breast02 HER2-positive, unresectable and/or metastatic breast cancer pretreated with prior standard of care HER2 therapies, including T-DM1
  • Enhertu DESTINY-Breast04 HER2-low, unresectable and/or metastatic breast cancer subjects
  • Enhertu (platform) DESTINY-Breast07 HER2+ breast cancer
  • Enhertu (platform) DESTINY-Breast08 HER2low breast cancer
  • Imfinzi CALLA locally-advanced cervical cancer
  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi PEARL 1st-line metastatic non-small cell lung cancer
  • Imfinzi (platform) BEGONIA 1st-line metastatic triple negative breast cancer
  • Imfinzi (platform) MAGELLAN 1st-line metastatic non-small cell lung cancer
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CRT KUNLUN Locally advanced esophageal squamous cell carcinoma
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CTx MERMAID-1 stage II-III adjuvant NSCLC
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx TOPAZ-1 1st-line biliary tract cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage II-III) non-small cell lung cancer
  • Imfinzi + FLOT MATTERHORN Neo-adjuvant/adjuvant gastric cancer
  • Imfinzi + SoC CASPIAN 1st-line extensive-stage small-cell lung cancer
  • Imfinzi + VEGF EMERALD-2 adjuvant hepatocellular carcinoma
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellular carcinoma
  • Imfinzi post-SBRT PACIFIC-4 stage I/II non-small cell lung cancer
  • Lynparza LYNK-003 platinum sensitive 1st-line colorectal cancer
  • Lynparza PROfound prostate cancer
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Lynparza (basket) MK-7339-002 / LYNK002 HRRm cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso LAURA stage III EGFRm non-small cell lung cancer
  • Tagrisso + CTx FLAURA2 1st-line advanced EGFRm non-small cell lung cancer
  • Tagrisso +/- CTx neoadjuvant NeoADAURA stage II/III resectable EGFRm NSCLC

Cardiovascular, Renal & Metabolism (as of 30 April 2021)

Phase I

Phase I

  • AZD2373 nephropathy
  • AZD2693 NASH
  • AZD3366 CV disease
  • AZD3427 CV disease
  • AZD9977 CV disease
  • MEDI8367 chronic kidney disease

Phase II

Phase II

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease / chronic kidney disease
  • AZD8233 CV disease
  • AZD8601 cardiovascular disease
  • cotadutide type-2 diabetes, obesity and NASH, diabetic kidney disease
  • MEDI3506 diabetic kidney disease
  • MEDI5884 cardiovascular disease
  • MEDI6570 cardiovascular disease
  • verinurad chronic kidney disease / HF with a preserved ejection fraction

Phase III

Phase III

  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end-stage renal disease

LCM Projects

LCM Projects

  • Brilinta/Brilique THALES acute ischaemic stroke or transient ischaemic attack
  • Brilinta/Brilique THEMIS cardiovascular outcomes trial in patients with coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke
  • Bydureon BCise (autoinjector) type-2 diabetes
  • Farxiga/Forxiga DAPA-CKD renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga DAPA-MI Prevention of heart failure and CV death following a myocardial infarction
  • Farxiga/Forxiga DELIVER worsening HF or CV death in patients with chronic heart failure (HFpEF)
  • roxadustat anaemia in myelodysplastic syndrome
  • roxadustat chemotherapy induced anaemia
  • Xigduo XR/Xigduo type-2 diabetes

Respiratory & Immunology (as of 30 April 2021)

Phase I

Phase I

  • AZD0284 psoriasis/respiratory
  • AZD0449 asthma
  • AZD1402 asthma

Phase II

Phase II

  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • AZD7986 chronic obstructive pulmonary disease
  • AZD9567 chronic inflammatory diseases
  • brazikumab EXPEDITION ulcerative colitis
  • MEDI3506 COPD/atopic dermatitis/asthma/COVID-19
  • navafenterol chronic obstructive pulmonary disease
  • tezepelumab atopic dermatitis
  • tezepelumab chronic obstructive pulmonary disease

Phase III

Phase III

  • anifrolumab TULIP 1 & TULIP 2 systemic lupus erythematosus
  • AZD7442 Prevention and treatment of COVID-19
  • brazikumab INTREPID crohns disease
  • COVID-19 Vaccine AstraZeneca COVID vaccine
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE severe uncontrolled asthma
  • nirsevimab passive RSV immunisation
  • PT027 asthma
  • tezepelumab NAVIGATOR severe uncontrolled asthma

LCM Projects

LCM Projects

  • Breztri/Trixeo (PT010) KALOS LAGOS asthma
  • Duaklir Genuair chronic obstructive pulmonary disease
  • Fasenra ARROYO chronic spontaneous urticaria
  • Fasenra HILLIER atopic dermatitis
  • Fasenra MANDARA eosinophilic granulomatosis with polyangiitis
  • Fasenra MESSINA eosinophilic esophagitis
  • Fasenra NATRON hypereosinophilic syndrome
  • Fasenra OSTRO ORCHID (Japan/China) nasal polyps
  • Fasenra RESOLUTE chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma

Other (as of 30 April 2021)

Phase I

Phase I

  • AZD4041 opioid use disorder
  • MEDI0618 osteoarthritis pain
  • MEDI1341 parkinson's disease
  • MEDI1814 alzheimer’s disease

Phase II

Phase II

  • MEDI7352 osteoarthritis pain and painful diabetic neuropathy
  • suvratoxumab prevention of nosocomial Staphylococcus aureus pneumonia

Phase III

Phase III

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis

Removed since last quarter